Although the mechanism of this inhibition needs to be further investigated, our results suggest that COX-2 may have a role in angiogenesis and may be a potential therapeutic target for the treatment of human osteosarcoma. Acknowledgements This research was supported by grants from the Shanghai Health Bureau Science Fund for Young Scholars (2009Y037), the https://www.selleckchem.com/products/sch-900776.html Technology Development Fundation of Shanghai Jiaotong University School of Medicine (09XJ21048). References 1. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P: Prognostic factors for Gefitinib concentration osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year

experience in 789 patients treated at a single institution. Cancer 2006, 106:1154–1161.PubMedCrossRef 2. Naruse T, Nishida Y, Hosono K, Ishiguro N: Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 2006, 27:584–592.PubMedCrossRef 3. Mirabello L, Troisi RJ, Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology,

and End Results Program. Cancer 2009, 115:1531–1543.PubMedCrossRef 4. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G: Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treatment Reviews 2006, 32:423–436.PubMedCrossRef 5. Yang G, Huang C, Cao J, Huang KJ, Jiang T, Qiu ZJ: Lentivirus-mediated shRNA interference targeting STAT3 inhibits human pancreatic cancer cell invasion. World J Gastroenterol 2009, 15:3757–3766.PubMedCrossRef 6. Brown JR, DuBois Repotrectinib in vitro RN: COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005, 23:2840–2855.PubMedCrossRef 7. Strillacci A, Griffoni C, Valerii Clomifene MC, Lazzarini G, Tomasi V, Spisni E: RNAi-based strategies for cyclooxygenase-2 inhibition in cancer. J Biomed Biotechnol 2010, 2010:828045.PubMedCrossRef 8. Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U: Expression of cyclooxygenase 2 in human malignant melanoma. Cancer

Research 2001, 61:303–308.PubMed 9. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60:1306–1311.PubMed 10. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL: Cyclooxygenase-2 is overexpressed in human cervical cancer. Clinical Cancer Research 2001, 7:429–434.PubMed 11. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S: Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001, 91:333–338.PubMedCrossRef 12. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705–716.PubMedCrossRef 13.